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Abstract A functional cDNA clone for the mouse prostaglandin 
I PG) E receptor EP 2 subtype was isolated from a mouse cDNA 
library. The mouse EP2 receptor consists of 362 amino acid 
residues with seven putative transmembrane domains. [3H]PGE2 
bound specifically to the membrane of Chinese hamster ovary 
tells stably expressing the cloned receptor. This binding was 
displaced by unlabeled prostanoids in the order of PGEz = 
I'GEt >> iloprost, a stable PGI 2 agonist > PGFz~ > PGDz. Bind- 
ing was also inhibited by butaprost (an EP2 agonist) and to a 
lesser extent by M&B 28767 (an EP 3 agonist), but not by sulpros- 
tone (an EP~ and EP 3 agonis0 or SC-19220 (an EP~ antagonist). 
PGE 2 and butaprost increased the cAMP level in the Chinese 
hamster ovary cells in a concentration-dependent manner. North- 
vrn blot analysis revealed that EP 2 mRNA is expressed most 
abundantly in the uterus, followed by the spleen, lung, thymus, 
ileum, liver, and stomach. 
gey words': Prostaglandin E2; Prostanoid EP 2 receptor: 
~issue distribution 
. Introduction 
Prostaglandin (PG) E2 produces a broad range of biological 
tctions in diverse tissues through binding to specific receptors 
m plasma membranes [1,2]. The pharmacological actions of 
OGE2 are diverse among tissues; PGE2 causes contraction or 
• elaxation of vascular and nonvascular smooth muscle, and 
;timulates or suppresses the secretion of neurotransmitters and 
mrmones. Pharmacological studies suggested that there are 
"our subtypes of PGE receptors, EP1, EP2, EP3 and EP 4, which 
ire thought o differ in their signal transduction mechanisms; 
:hey are presumed to be coupled to Ca 2+ mobilization, and the 
~timulation, inhibition, and stimulation of adenylate cyclase, 
respectively [3 5]. Among the four subtypes, EP2 and EP 4 are 
:oupled to the same signal transduction pathway, stimulation 
af adenylate cyclase, but differ in their activities induced by 
some ligands including butaprost and AH23848B [5-7]. While 
EP2 is sensitive to butaprost, EP4 is insensitive tobutaprost but 
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sensitive to AH23848B. PGE 2 has been shown to increase the 
cAMP level in many tissues and cells [1], suggesting that the EP2 
and/or EP 4 receptor is widely distributed and mediates various 
actions of PGE,. However, it remains unclear which EP recep- 
tor contributes to each action of PGE 2 in various tissues. We 
have isolated cDNAs for three subtypes of mouse PGE recep- 
tor, EP L, EP3, and EP4. Using these mouse clones, we character- 
ized their structural, binding and signaling properties and tissue 
distribution [6,8 10]. Recently, Regan et al. cloned a human 
PGE receptor, which is similar in its ligand binding properties 
to the pharmacologically defined EP 2 subtype [11]. However, 
tissue distribution study using the human clone has not been 
well established because of the restriction of available human 
tissues. Furthermore, the results of various pharmacological 
studies have been interpreted to indicate that there are differ- 
ences among prostanoid receptors from different species [3]. It 
is important to examine the properties of the receptor mole- 
cules from identical species to understand the actions of pro- 
stanoids. For the purpose of comparative analyses in the mouse 
PGE receptors, we cloned a cDNA for the mouse EP 2 receptor 
by PCR and hybridization screening. Using this clone, we 
found that the EP~ receptor mRNA is widely distributed 
throughout various mouse tissues and expressed most abun- 
dantly in the uterus. We also present here the primary structure 
of the mouse EP 2 receptor, together with those of the other 
seven mouse prostanoid receptors. 
2. Materials and methods 
2.1. Materials 
Butaprost, SC-19220 and misoprostol, M&B 28767, and sulprostone 
were generous gifts from Dr. RJ. Gardiner of Bayer UK Ltd., Dr. P.W. 
Collins of Searle, Dr. M.EL. Caton of Rhone-Poulenc Ltd., and Scber- 
ing, respectively. [5,6,8,9,11,12,14,15--~H]PGE2 ( 181 Ci/mmol), iloprost, 
and the ~2q-labeled cyclic AMP assay system were obtained from Amer- 
sham Corp. [~-~eP]dCTP (3,000 Ci/mmol) and [~-~2p]UTP (3,000 Ci/ 
mmol) were obtained from DuPont-New England Nuclear, PGE2. 11- 
deoxy-PGE~ 19(R)OH-PGE> I-OH-PGE> and 16,16-dimethyl-PGE~ 
were purchased from Cayman Chemical (Ann Arbor, MI). PGG, 
PGF2~ and PGD, were obtained from Funakoshi Pharmaceuticals 
(Tokyo, Japan). Sources of other materials are shown in the text. 
2.2. Ampl(hcation fa eDNA fi'agment o[' the mouse EP: receptor by 
PCR 
First-strand eDNA was synthesized from mouse lung total RNA 
using random hexanucleotides as primers. Degenerate PCR primers, 
5'-CTGGGATCCATGCTCATGCT(CG)TT(CT)GC(ACGT)ATGG- 
C-3' and 5'-GCAGAATTCAGACGGCGAA(CG)GT(AG)AT(GTF 
GTCAT-3', corresponding to the putative third and sixth transmem- 
brane domains of the human EP 2 receptor [11] were synthesized. The 
thermal cycle program was 94°C for 0.8 min, 48°C for 1 min, 72°C for 
3 min for the first 2 cycles, 94°C for 0.8 min, 50°C tbr 1 min, 72°C for 
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2 min for the next 3 cycles, followed by 94°C for 0.8 min, 55°C for 
1 min, 72°C for 3 min for 27 cycles. Amplified cDNAs were subcloned 
into pBluescript II SK(+) (Stratagene). A 466-base pair clone showed 
a sequence highly homologous to the human EP2 receptor cDNA. 
2.3. Isolation of a functional cDNA clone 
A mouse lung cDNA library was prepared as described previously 
[12]. Approximately 3.0 x 105 recombinant clones from this library were 
screened by hybridization with the cDNA fragment obtained by PCR. 
Hybridization was carried out under the conditions described previ- 
ously [13]. Four positive clones were isolated, and a representative 
clone, ML202, was subjected to sequence and expression analyses. 
Nucleotide sequencing was carried out on both strands by the dideoxy 
chain termination method. 
2.4. Expression in CHO cells and functional analyses 
The EcoRI insert of ML202 was subcloned into pdKCR-dhfr [14], 
and the resultant plasmid DNA was transfected into Chinese hamster 
ovary (CHO) cells deficient in dihydrofolate r ductase activity (CHO- 
dhfr-) by the lipofection method [15]. Establishment ofCHO cell clones 
stably expressing the receptor was performed essentially as described 
previously [9]. Using the crude membrane fraction prepared from a 
CHO cell clone expressing the receptor, [3H]PGE~ binding was deter- 
mined as described previously [6]. The cAMP levels in the CHO cell 
clone were measured as described [6]. 
2.5. Northern blot analysis 
Total RNAs from various mouse tissues were isolated by the acid 
guanidinium thiocyanate/phenol/ehloroform method [16], and poly(A) + 
RNAs were purified using Oligotex dT30 < Super > (Takara Shuzo, 
Kyoto, Japan). For the detection of EP2 transcripts, 5Pg of poly(A) ÷ 
RNAs purified twice with the Oligotex from various tissues were sepa- 
rated by electrophoresis on a 1.2% agarose gel, and transferred onto 
a nylon membrane (Hybond-N, Amersham). An antisense RNA probe 
was synthesized with T7 RNA polymerase using linearized ML202 as 
the template. For the detection of the EP4 mRNA, 5/lg of poly(A)+-rich 
RNA (purified once with the Oligotex) was used. An antisense RNA 
probe was synthesized with T7 RNA polymerase using linearized 
MP412 with the XhoI fragment deleted as the template. Hybridization 
was carried out at 70°C for 4 h in 5 x SSC, 50% formamide, 5 x Den- 
hardt's solution, 0.2% SDS, 0.05 M sodium phosphate (pH 6.5), 
250 pg/ml heat-denatured salmon sperm DNA, 200/lg/ml yeast ransfer 
RNA, and the 32p-labeled probe. Filters were washed at 70°C in 
2 × SSC and 1% SDS for 10 rain, in 0.2 × SSC and 0.5% SDS for the 
next 10 rain, and then in 0.1 × SSC and 0.l% SDS for 20 min. The filter 
for detecting the EP4 mRNA was treated with 1 pg/ml RNase A at 20 ° C 
for 10 min, and washed again at 70°C in 0.1 × SSC and 0.1% SDS for 
10 rain. 
3. Results and discussion 
A mouse cDNA clone, ML202, was isolated by PCR and 
subsequent screening of a mouse lung cDNA library. Fig. 1 
shows the nucleotide and deduced amino acid sequences of 
ML202. ML202 contains a 1.7-kilobase (kb) insert which has 
an open reading frame of 1,086 base pairs. The deduced amino 
acid sequence showed that it encodes a protein of 362 amino 
acid residues with an estimated molecular weight of 40,478. The 
ATG assigned as the initiation codon matched well to the 
Kozak consensus equence for translation initiation [17]. Anal- 
ysis of the predicted amino acid sequence indicated that it 
possesses seven hydrophobic segments typical of guanine nucle- 
otide-binding protein-coupled rhodopsin-type r ceptors, and is 
86% identical to that of the human EP2 receptor [11]. Two 
potential N-glycosylation sites [18] were found in the N-termi- 
nal and the first extracellular loop regions. Five potential sites 
of phosphorylation by protein kinase C [19] were found in the 
second and third intracellular loops and the C-terminal regions. 
Membranes of CHO cells expressing the cloned receptor 
showed specific binding of [3H]PGE2. Scatchard analysis of this 
binding yielded a dissociation constant of 26.7 nM and maximal 
binding of 822 fmol/mg protein. Fig. 2 shows the specificity of 
-145 GTGCGAGTTGGGGGCCGGAAGGGAG -121 
CTCTGGATTTCGGTCCCTC ~C~TTTTCCCTGCTCTGTCTTGGAGCCCTG~CATCAGACC~TCCGA~TGTCTGGTACTTGCCTGGAAGAGATAT~ATCTCTCCTC~ACA~ CCTCCACC - 1 
ATGGACAATTTTC TTAATGACTCCAAGC TAATGGAGGAC TGCAAGAGTC GTCAGTGGC TCCTTTC GGGGGAAAGCC CAGCCATCAGC TC GGTGATGTTCTC GGC C GGGGTTC TGGGGAAT 120 
M D N F L N D S K L M E D C K S R Q W L L S G E ~ P A I S S V M F S A G V L G N 40 
n I 
CT~ATCGCACTGG~ACTGTTGGCGCGCCGCTGGCGTGGGGACACCGGGTGTAGCG~CGGCAGCAGGACCTCTATCTC~TTGTTTCACGTGCT~T~C~T~Ac~AcCTG 240 
L I A L A L L A R R W R G D T G C S A G S R T S I S L F H V L V T E L V L T D L 80 
II 
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A III 
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S L A T M L M L F A M A L E R Y L S I G Y P Y F Y R R H L S R R G G L A V L P V 160 
• IV 
A TC TATGGGGC TCCTTGC TCTTCTGTTCCC TGC CGC TGCTCAACTACGGGGAGTACGTCCAGTACTGTC CTGGGACATGGTGCTTTATC  GGC ACG GGAGGACTGCATACCTTC A~ ~ 600 
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TACGC CACGATGC TCC TGC TGC TTATCGTGGCTGTC, C TCGCCTGCAACATCAGCGTTATC C TCAACCTCATTC GCATGCAC C GTC GGAGCAGAAGAAGC C GCTGC GGATTGTCTGGCAGT 720 
Y A T M L L L L I V A V L A C N I S V I L N L I R M H R R S R R S R C G L S G S 240 
AGC C TAAGAGGC CTGGATCTCGCAGGAGAGGAGAGAGGACTTC GATGGCAGAGGAGACGGACCAC CTCATTC TCC TGGCCATTATGAC ATCAC CTTC GCCATAT GCTC C TTGC C TTTC 840 
S L R G P G S R R R G E R T S M A E E T D H L I L L A I M T r T F A I C S L P F 280 
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C CCTTTTAAAAAAAAA 1576 
Fig. 1. Nucleotide and deduced amino acid sequences of ML202. The deduced amino acid sequence is shown beneath the nucleotide sequence using 
the single-letter code. The positions of the putative transmembrane s gments, I-VII, are underlined. Triangles = potential N-glycosylation sites; 
parallel crosses = potential sites of phosphorylation by protein kinase C. 
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:ig. 2. Binding of [3H]PGE2 to ML202-expressing CHO cell membranes. (a) Displacement of[3H]PGE2 binding by various prostanoids. Membranes 
~f CHO cells expressing ML202 were incubated with 4 nM [3H]PGE2 and various unlabeled prostanoids atthe concentrations indicated. Q = PGE2; 
• = PGE~; ~ = iloprost; • = PGF2~; zx = PGD2. (b) Displacement of [3H]PGE2 binding by ligands for PGE receptor subtypes. • = butaprost; 
= M&B 28767; • = sulprostone; z5 = SC-19220. (c) Displacement of [3H]PGE2 binding by other EP agonists. • -- 16,16-dimethyl-PGE2; [] =ll- 
leoxy-PGE~; • = misoprostol; z~ = 19(R)OH-PGE2; • = 1-OH-PGE~. The same data for PGE. as shown in (a) are displayed in (b) and (c). 
'..his binding. As shown in Fig. 2a, specific [3H]PGE2 binding 
was displaced by unlabeled prostanoids in the order of PGE2 = 
PGE~ -> iloprost, a stable PGI2 agonist > PGF:~ > PGD2. This 
result indicates that ML202 encodes a specific PGE receptor. 
~s shown in Fig. 2b, further analyses using several igands 
specific to PGE receptor subtypes demonstrated that the bind- 
ing was also inhibited by butaprost (an EP2 agonist) and to a 
lesser extent by M&B 28767 (an EP 3 agonist), but not by sul- 
prostone (an EPt and EP3 agonist) and SC-19220 (an EPI antag- 
onist). These results indicate that ML202 encodes the mouse 
EP2 receptor. We further characterized the binding specificity 
of the mouse EP2 receptor for various ligands including EP2 
agonists. As shown in Fig. 2c, specific [3H]PGE2 binding was 
also inhibited by several ligands in the order of 16,16-dimethyl- 
PGE2 (a nonselective EP agonist) [6,11] > 11-deoxy PGE~ (an 
EP2, EP3, and EP4 agonist) [6,11] > misoprostol (an EPz, EP3, 
and EP4 agonist) [10,20,21] > 1-OH-PGE~ (an EP4 partial ag- 
onist) [6] > 19(R)OH-PGE 2(an EP 2 agonist) [11,22]. This bind- 
ing characteristic was in good agreement with that of the 
human EP2 receptor [11], except for the poor reactivity of 
19(R)OH-PGE2 to the mouse receptor. This may have been at 
least in part due to species difference between the two recep- 
tors. 
Fig. 3 shows the comparison of the amino acid sequences 
among the cloned mouse prostanoid receptors [8-10, 
12,13,23,24]. The EP 2 receptor showed a higher degree of 
homology to the DP, IP, and EP4 receptors than to the other 
prostanoid receptors. It is intriguing phylogenetically that the 
EP 2, DP, IP, and EP4 receptors are all coupled to stimulation 
of adenylate cyclase. Among these receptors, the EP: receptor 
possesses higher sequence homology with the DP and IP recep- 
tors rather than with the EP 4 receptor; the EP 2 receptor shares 
44%, 39%, and 31% overall amino acid identity with the DR 
IR and EP4 receptors, respectively. This indicates that the 
divergence between the EP2 and EP4 receptors occurred before 
the derivation of the DP and IP receptors from the EP 2 receptor 
[251. 
We next examined the signal transduction pathway of the 
mouse EP2 receptor. As shown in Fig. 4, PGE2 generated 
cAMP in a concentration-dependent manner in CHO cells ex- 
pressing the EP 2 receptor. In addition, butaprost and 11-deoxy- 
PGE~ were also effective in stimulating cAMP formation in the 
cells, although their half-maximal concentrations for this effect 
were about 10-tbld higher than that of PGE 2. 19(R)OH-PGE2 
and 1-OH-PGE1 were less effective than the ligands described 
above. We also examined whether PGE2 induces accumulation 
of inositol phosphates, but PGE 2 did not evoke phosphatidyli- 
nositol hydrolysis in the cells (data not shown), as in the case 
of the EP 4 receptor [10]. 
PGE 2 has been shown to increase the cAMP level in many 
tissues and cells [1] through its interaction with the EP2 and/or 
EP 4 receptors. To elucidate which EP receptor subtype is in- 
volved in cAMP-mediating actions of PGE2 in each tissue, we 
compared the expression patterns of the EP2 and EP 4 receptors 
by Northern hybridization. As shown in Fig. 5a, the level of EP2 
expression was much lower than that of the EP4 in most of the 
tissues examined. In the previous report, using standard hybrid- 
ization analysis, Regan et al. detected an EP 2 message only in 
the mRNA from human placenta nd lung, but not in the other 
tissues [11]. We, therefore, utilized highly purified poly(A) ÷ 
RNAs for more sensitive detection (Fig. 5b). As a result, a 
positive band at 2.2 kilobase was detected in a number of tissues 
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mDP QAK~RFLSVISXVDPWIFX IFRTS%rFRM-LFHKVFTRPL IYRNWSSHSQQ sNVESTL  357  
mIP  LAFRFNAFNPxLD1~rFxLF~KAvFQR-LKFWLCCLCARSVHGDLQAPL8RPASGRRD~PAPTSLQAKEGSWVPLSSWGTGQVA(3~)  416  
mEP4 QAIR IA8VNPzLD~WIYx~TvLSKAIEK IKCLFC~IGGSGRDSSAQHCSESRRTSSAMSGHSRSFLARELKE ISSTSQTL(9~)  513  
mEP3a IAV I~L4&SL~Znn l~r%'LL I JKK IL I~RK-FCQIRDHTNYASSSTSLPCPGSSALMWSDQ LER 365  
mEP I  -AVP J .~KSWNQZLDI~tVYZ~QAMLRQ-LLRLLPLRVSAKGGPTELGLTKSAWEASSLRSSRHSGFSHL 405 
mFP FA~RMATW~ZLDIW0%~fXT~I~'~AVLRN-LYKLASRCCGVNI ISLHIWELSS IKNSLKVAAISESPAAEKESQQ ASSEAGL 366 
mTP IYLRVA~XLDI~VYXLFRRS%~W~R-LHPRFSSQLQAVSLRRPPAQAMLSGP 341  
Fig. 3. Comparison of the amino acid sequences of mouse prostanoid receptors. The deduced amino acid sequences of the mouse EP2 receptor (mEP2), 
mouse PGD receptor (mDP), mouse PGI receptor (mlP), mouse EP4 (mEP4), mouse EP3~ receptor (mEP3ct), mouse EP~ receptor (mEPI), mouse 
PGF receptor (mFP), and mouse TXA2 receptor (mTP) are aligned to optimize homology. Identical amino acid residues in four or more sequences 
are indicated by bold characters. The approximate positions of the putative transmembrane regions are indicated above the amino acid sequences. 
in which the EP2 receptor has been identified in the pharmacol- 
ogical studies [3]; the tissues include the uterus, lung, ileum, 
liver, stomach, thymus and spleen. Another hybridizing band 
was also seen at 2.8 kilobase in the uterus, lung, thymus and 
spleen. These data demonstrate that the EP 2 receptor was 
widely distributed throughout the mouse tissues. 
The highest level of EP 2 mRNA expression was seen in the 
uterus, in which EP4 was also expressed. As reported previ- 
ously, EP~ is also expressed in the uterus [9]. PGE2 can cause 
both relaxation and contraction of myometrium [26]. There- 
fore, in the uterus the relaxant activity of PGE2 may be exerted 
via EP 2 and/or EP4, and the contractile response may be medi- 
ated via EP 3. Both EP 2 and EP 4 are expressed in the ileum and 
thymus. PGE 2 and butaprost were reported to cause relaxation 
of ileal smooth muscle [27], while PGE 2 also stimulates intesti- 
nal secretion via elevation of mucosal cAMP level [28-30]. It 
is likely that EP 2 and EP4 are involved in relaxation of intestinal 
smooth muscle and stimulation of intestinal secretion, respec- 
tively. The EP2 transcript was detected in the liver, in which no 
signals for the EP4 receptor were detected. PGE2 was reported 
to be involved in liver regeneration [31], and PGE2 and other 
cAMP-elevating agents can induce the expression of hepatocyte 
growth factor [32]. EP2 might be involved in these actions of 
PGE2. EP2 was also expressed in the spleen, lung, and stomach. 
In the lung, the other PGE receptors are also expressed [8,9], 
but EP 2 may be partly involved in PGE2-induced relaxation of 
the trachea [7]. 
In summary, we presented in this paper the primary struc- 
ture, ligand binding profile, signaling pathway, and tissue dis- 
tribution of the mouse PGE receptor EP 2 subtype. Distribution 
analyses of EP2 and EP4 in the mouse tissues uggested that 
PGE2 exerts multiple functions via these receptor subtypes dif- 
ferentially expressed in the body. This work will be useful for 
understanding the diverse physiological roles of PGE2 mediated 
through multiple receptor subtypes. 
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Fig. 5. Northern blot analysis of RNAs isolated from various mouse 
tissues. (a) Comparison of the levels of expression of the mouse EP, 
receptor (upper) and EP4 receptor (lower). Poly(A)+-rich RNA (5/zg) 
was applied to each lane. (b) Tissue distribution of the mouse EP2 
receptor. Highly purified poly(A) ÷ RNA (5/zg) was applied to each 
lane. Hybridization analysis was carried out as described in section 2. 
Lane 1 = brain; lane 2 = thymus; lane 3 = lung; lane 4 = heart; lane 
5 = liver; lane 6 = stomach; lane 7 -- spleen; lane 8 = ileum: lane 
9 = kidney; lane 10 = testis; lane 11 = uterus. 
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